Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 /g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Ascendis Pharma A/S

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

COPENHAGEN, DENMARK, MARCH 02, 2026 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNOUNCED THAT COMPANY EXECUTIVES WILL PARTICIPATE IN A VIRTUAL FIRESIDE CHAT AT THE TD COWEN 46TH ANNUAL HEALTH CARE CONFERENCE ON MONDAY, MARCH 2, 2026, AT 11:10 A.M. EASTERN TIME / 8:10 A.M. PACIFIC TIME IN BOSTON, MASSACHUSETTS.

ASCENDIS PHARMA TO PARTICIPATE IN THE TD COWEN 46TH ANNUAL HEALTH CARE CONFERENCE

COPENHAGEN, DENMARK, FEB. 27, 2026 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNOUNCED THAT THE U.S. FOOD & DRUG ADMINISTRATION (FDA) HAS GRANTED APPROVAL UNDER THE FDA'S ACCELERATED APPROVAL PROGRAM FOR YUVIWEL (NAVEPEGRITIDE; DEVELOPED AS TRANSCON CNP), THE FIRST AND ONLY ONCE-WEEKLY TREATMENT INDICATED TO INCREASE LINEAR GROWTH IN CHILDREN 2 YEARS OF AGE AND OLDER WITH ACHONDROPLASIA WITH OPEN EPIPHYSES AND THE ONLY ONE TO PROVIDE CONTINUOUS SYSTEMIC EXPOSURE TO CNP OVER THE WEEKLY DOSING INTERVAL. CONTINUED APPROVAL FOR THIS INDICATION, WHICH WAS BASED ON AN IMPROVEMENT IN ANNUALIZED GROWTH VELOCITY (AGV), MAY BE CONTINGENT UPON VERIFICATION AND DESCRIPTION OF CLINICAL BENEFIT IN CONFIRMATORY TRIAL(S).

FDA APPROVES ONCE-WEEKLY YUVIWEL (NAVEPEGRITIDE) FOR CHILDREN WITH ACHONDROPLASIA AGED 2 YEARS AND OLDER

COPENHAGEN, DENMARK, FEB. 11, 2026 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2025, AND PROVIDED A BUSINESS UPDATE.

ASCENDIS PHARMA REPORTS FOURTH QUARTER AND FULL-YEAR 2025 FINANCIAL RESULTS

COPENHAGEN, DENMARK, FEB. 04, 2026 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNOUNCED IT PLANS TO REPORT FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDE A BUSINESS UPDATE ON WEDNESDAY, FEBRUARY 11, 2026, AFTER THE CLOSE OF THE U.S. FINANCIAL MARKETS. ASCENDIS PHARMA ALSO PLANS TO HOST A CONFERENCE CALL AND LIVE WEBCAST ON FEBRUARY 11, 2026, AT 4:30 P.M.

ASCENDIS PHARMA TO REPORT FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON FEBRUARY 11, 2026

COPENHAGEN, DENMARK, JAN. 09, 2026 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY PROVIDED A BUSINESS AND STRATEGIC ROADMAP UPDATE, INCLUDING PLANNED 2026 KEY CORPORATE MILESTONES. ASCENDIS PRESIDENT AND CEO JAN MIKKELSEN WILL PRESENT THIS UPDATE ON MONDAY, JANUARY 12, DURING THE 44TH ANNUAL J.P.

ASCENDIS PHARMA PROVIDES BUSINESS AND STRATEGIC ROADMAP UPDATE AT 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

 ONCE-WEEKLY TRANSCON  CNP AND TRANSCON  HGH COMBINATION THERAPY SHOWED DURABLE GROWTH WITHOUT COMPROMISING SAFETY OR TOLERABILITY AT 52 WEEKS  ANNUALIZED GROWTH VELOCITY (AGV) EXCEEDED THE 97TH-PERCENTILE OF AVERAGE STATURE CHILDREN  ACH HEIGHT Z-SCORE IMPROVEMENTS INDICATED A TRIPLING OF EFFICACY COMPARED TO TRANSCON CNP MONOTHERAPY  COMBINATION THERAPY DEMONSTRATED BENEFITS BEYOND LINEAR GROWTH WITH IMPROVEMENTS IN BODY PROPORTIONALITY AND ARM SPAN, ALIGNING WITH THE INCREASE IN LINEAR GROWTH  ALL CHILDREN COMPLETED 52 WEEKS OF TREATMENT AND REMAIN ON THERAPY IN COACH AS OF TODAY  COMBINATION THERAPY WAS GENERALLY WELL TOLERATED, WITH GENERALLY MILD TREATMENT-EMERGENT ADVERSE EVENTS (TEAES), CONSISTENT WITH TRANSCON CNP AND TRANSCON HGH MONOTHERAPIES  ASCENDIS TO HOST CONFERENCE CALL TODAY AT 4:30PM ET COPENHAGEN, DENMARK, JAN. 08, 2026 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNOUNCED TOPLINE RESULTS FROM WEEK 52 OF COACH, THE FIRST PHASE 2 CLINICAL TRIAL TO EVALUATE COMBINATION THERAPY WITH ONCE-WEEKLY TRANSCON CNP (NAVEPEGRITIDE) AND ONCE-WEEKLY TRANSCON HGH (LONAPEGSOMATROPIN) IN CHILDREN WITH ACHONDROPLASIA. AT WEEK 52, COMBINATION THERAPY SHOWED DURABLE GROWTH WITHOUT COMPROMISING SAFETY OR TOLERABILITY.

WEEK 52 COACH TRIAL TOPLINE RESULTS CONFIRM CONSISTENT AND DURABLE TREATMENT BENEFITS IN CHILDREN WITH ACHONDROPLASIA (ACH)

COPENHAGEN, DENMARK, JAN. 05, 2026 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNOUNCED THAT COMPANY EXECUTIVES WILL PARTICIPATE IN THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE AND PROVIDE A BUSINESS UPDATE ON MONDAY, JANUARY 12, 2026, AT 10:30 A.M. EASTERN TIME / 7:30 A.M. PACIFIC TIME IN SAN FRANCISCO, CALIFORNIA.

ASCENDIS PHARMA TO PARTICIPATE IN THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

 PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE EXTENDED BY THREE MONTHS TO FEBRUARY 28, 2026 COPENHAGEN, DENMARK, NOV. 25, 2025 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNOUNCED THAT THE U.S. FOOD & DRUG ADMINISTRATION (FDA) NOTIFIED THE COMPANY THAT INFORMATION SUBMITTED ON NOVEMBER 5, 2025, RELATED TO THE POST-MARKETING REQUIREMENT, IN RESPONSE TO THE FDA'S ONGOING REVIEW OF THE NEW DRUG APPLICATION (NDA) FOR TRANSCON CNP (NAVEPEGRITIDE) FOR CHILDREN WITH ACHONDROPLASIA, CONSTITUTED A MAJOR AMENDMENT TO THE NDA. ACCORDINGLY, THE FDA HAS EXTENDED THE PDUFA TARGET ACTION DATE BY THREE MONTHS TO FEBRUARY 28, 2026.

ASCENDIS ANNOUNCES EXTENSION OF FDA REVIEW PERIOD FOR TRANSCON CNP (NAVEPEGRITIDE) FOR CHILDREN WITH ACHONDROPLASIA

COPENHAGEN, DENMARK, NOV. 17, 2025 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNOUNCED THAT PIVOTAL WEEK 52 RESULTS FROM ITS RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED APPROACH TRIAL OF INVESTIGATIONAL ONCE-WEEKLY TRANSCON CNP (NAVEPEGRITIDE) IN CHILDREN WITH ACHONDROPLASIA HAVE BEEN PUBLISHED IN JAMA PEDIATRICS, A JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. IN THE PUBLICATION, TITLED ONCE-WEEKLY NAVEPEGRITIDE IN CHILDREN WITH ACHONDROPLASIA: THE APPROACH RANDOMIZED CLINICAL TRIAL, THE AUTHORS REPORT THAT TREATMENT WITH TRANSCON CNP LED TO SIGNIFICANTLY HIGHER ANNUALIZED GROWTH VELOCITY (AGV) AT WEEK 52 COMPARED TO PLACEBO (PRIMARY ENDPOINT), AS WELL AS IMPROVED LOWER-LIMB ALIGNMENT AND BODY PROPORTIONALITY AND POSITIVE CHANGES IN HEALTH-RELATED QUALITY OF LIFE, WITH A SAFETY AND TOLERABILITY PROFILE SIMILAR TO PLACEBO. THE ABSTRACT CAN BE ACCESSED ON THE JAMA PEDIATRICS WEBSITE.

RESULTS OF PIVOTAL APPROACH TRIAL OF TRANSCON CNP (NAVEPEGRITIDE) IN CHILDREN WITH ACHONDROPLASIA PUBLISHED IN JAMA PEDIATRICS

 Q3 2025 REVENUE OF 143.1 MILLION FOR YORVIPATH  AND 50.7 MILLION FOR SKYTROFA 

Ascendis Pharma A/S

ASND

Price

Financial Reports

No items found.

Press Releases

Ascendis Pharma A/S

ASND.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ASND